.jpg)
Avidity's latest DMD data drop assuages safety concerns for RNA-based asset: analyst
After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based Duchenne muscular dystrophy candidate.
After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based Duchenne muscular dystrophy candidate.
